Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 2.4mg equivalent 1.5 mg rivastigmine;   - capsule - 1.5 mg - active: rivastigmine tartrate 2.4mg equivalent 1.5 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 1.6mg equivalent to 1 mg rivastigmine - capsule - 1 mg - active: rivastigmine tartrate 1.6mg equivalent to 1 mg rivastigmine excipient: colloidal silicon dioxide gelatin   hypromellose iron oxide red iron oxide yellow   magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv titanium dioxide   - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 4.8mg equivalent 3 mg rivastigmine;   - capsule - 3 mg - active: rivastigmine tartrate 4.8mg equivalent 3 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 7.2mg equivalent to 4.5 mg rivastigmine;   - capsule - 4.5 mg - active: rivastigmine tartrate 7.2mg equivalent to 4.5 mg rivastigmine   excipient: colloidal silicon dioxide gelatin hypromellose iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose opacode white s-1-18086 titanium dioxide - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 9.6mg equivalent to 6 mg rivastigmine;   - capsule - 6 mg - active: rivastigmine tartrate 9.6mg equivalent to 6 mg rivastigmine   excipient: colloidal silicon dioxide gelatin   hypromellose iron oxide red   iron oxide yellow   magnesium stearate microcrystalline cellulose tekprint red sw-1102 titanium dioxide   - indicated in the treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimers disease or alzheimers disease.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base;   - oral solution - 2 mg/ml - active: rivastigmine tartrate 3.2 mg/ml equivalent to 2 mg/ml rivastigmine base   excipient: citric acid monohydrate purified water quinoline yellow sodium benzoate sodium citrate dihydrate - treatment of patients with mild to moderately severe dementia of the alzheimer type, also termed probable alzheimer's disease or alzheimer's disease.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - letrozole 2.5mg;   - film coated tablet - 2.5 mg - active: letrozole 2.5mg   excipient: colloidal silicon dioxide hypromellose as 0.087 mg pigment suspension white + 0.087 mg pigment suspension yellow + 1.663 mg additional iron oxide yellow lactose monohydrate macrogols magnesium stearate maize starch microcrystalline cellulose purified talc sodium starch glycolate titanium dioxide - adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer extended adjuvant treatment of invasive early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy for five years. first-line treatment in postmenopausal women with advanced breast cancer advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac potassium 50mg;   - powder for oral solution - 50 mg - active: diclofenac potassium 50mg   excipient: aspartame anise flavour mint flavour glyceryl dibehenate mannitol potassium bicarbonate saccharin sodium - - post-traumatic pain, inflammation and swelling (e.g. due to sprains). - post-operative pain, inflammation and swelling (e.g. following dental or orthopaedic surgery). - painful and/or inflammatory conditions in gynaecology (e.g. primary dysmenorrhoea or adnexitis). - migraine attacks. - painful syndromes of the vertebral column. - non-articular rheumatism. - as an adjuvant in severe painful inflammatory infections of the ear, nose or throat e.g. pharyngotonsilitis, otitis. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. fever alone is not an indication.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - calcium folinate pentahydrate 12.71 mg/ml equivalent to 10 mg/ml folinic acid - concentrate for injection - 10 mg/ml - active: calcium folinate pentahydrate 12.71 mg/ml equivalent to 10 mg/ml folinic acid excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - · as rescue therapy to reduce toxicity following high-dose methotrexate therapy. · has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions · overdosage of methotrexate and in impaired methotrexate elimination · reducing the toxicity and circumventing the effect of folic acid antagonists

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for injection - 20 mg/2ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol macrogol 300 polysorbate 80